Latest news with #tumorprofiling
Medscape
2 days ago
- Health
- Medscape
Multiomics Platform May Guide Melanoma Treatment
TOPLINE: The novel Tumor Profiler (TuPro) project, which analyzed melanoma samples using nine independent technologies, demonstrated feasibility in guiding treatment decisions. Molecular tumor board recommendations on the basis of TuPro were deemed useful in 75% of cases. METHODOLOGY: Despite advances in melanoma therapy, many patients experience relapse and lack effective treatment options. Multiomics and single-cell profiling promise comprehensive tumor insights but require evaluation for feasibility and clinical utility in guiding treatment decisions. Researchers conducted a prospective, multicentric observational project (TuPro) enrolling 116 patients with any subtype of melanoma, from whom 126 biopsy samples were collected at three Swiss hospitals from January 2019 to November 2020. The TuPro application cohort included 93 patients (103 biopsy samples). The biopsies were analyzed using nine independent technologies, including single-cell genomics, transcriptomics (single-cell RNA sequencing [scRNA-seq]), targeted proteomics (imaging mass cytometry [IMC]), drug phenotyping (Pharmacoscopy), and digital pathology, which generated up to 500 Gb of data per sample within a 4-week turnaround time. The molecular tumor board evaluated data from all technologies to inform treatment recommendations across three patient groups: adjuvant setting (n = 13), palliative standard of care (n = 45), and palliative beyond standard of care (n = 37). The median follow-up duration was 20.5 months. TAKEAWAY: Patients in the palliative standard-of-care group achieved an objective response rate of 60% and a disease control rate of 62%, whereas those in the palliative beyond standard-of-care group achieved an objective response rate of 38% and a disease control rate of 54%. In a matched analysis of patients who received at least three treatment lines, the median progression-free survival reached 8.34 months in the TuPro cohort vs 2.0 months in the non-TuPro cohort (adjusted hazard ratio, 0.23; 95% CI, 0.07-0.79; adjusted P = .0201), suggesting benefit in heavily pretreated patients. Molecular data from TuPro were considered useful by the multidisciplinary molecular tumor board in 75% of evaluated cases, representing a 39% and 33% increase in concordance vs standard clinical workup alone (diagnostic levels 1 and 2, respectively). The TuPro workflow led to actual therapies in 87% of cases. A minimal set of four technologies (next-generation DNA sequencing [NGS], IMC, Pharmacoscopy, and scRNA-seq) could cover all 54 markers used for treatment decision-making at 1.15-fold higher costs than those for the standard NGS for adjuvant or palliative standard-of-care settings and 1.8-fold higher costs than those for the palliative beyond standard-of-care setting. IN PRACTICE: 'This study demonstrates the feasibility of using advanced multiomics approaches, including spatial proteomics, to guide therapy decisions in late-stage melanoma — one of the most aggressive and treatment-resistant cancers — with a reproducible patient benefit,' said Stéphane Chevrier, PhD, CSO, and cofounder of Navignostics and contributor to the TuPro study, in a press release. 'This is a major step toward pan-cancer diagnostics. By providing a comprehensive view of the tumor biology, the approach could eventually identify features that are predictive for treatments across cancer indications.' SOURCE: The study, led by Nicola Miglino, the University of Zurich and University Hospital, Zurich, Switzerland, was published online in Nature Medicine. LIMITATIONS: The current approach of selecting markers for treatment decisions by human experts did not capture all potentially relevant information. The retrospective comparison between TuPro and non-TuPro cohorts limited extrapolation and generalizability of the results. Additionally, definitive conclusions about the clinical value of serial sampling cannot be drawn owing to heterogeneous results and a small sample size. DISCLOSURES: The study received an open-access funding from the University of Zurich. Several authors reported having advisory roles or receiving research funding and having other ties with various pharmaceutical companies. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Associated Press
30-06-2025
- Business
- Associated Press
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
FORT MYERS, Fla.--(BUSINESS WIRE)--Jun 30, 2025-- NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently. PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabling physicians to rapidly initiate treatment strategies. Minimal specimen requirements make it suitable for a wide range of tumor types and practice settings. The assay builds on the company's tissue-based CGP platform, previously known as NeoComprehensive ® Solid Tumor. The addition of PanTracer Tissue + HRD offers enhanced tumor profiling by incorporating homologous recombination deficiency analysis into a single, guideline-aligned test for ovarian cancer. The PanTracer Tissue + HRD offering includes BRCA mutation status and a genomic instability score—critical biomarkers that can help guide the use of PARP inhibitors and other therapies targeting DNA repair pathways. The combined approach streamlines ordering and can shorten time to actionable results by capturing a broader range of clinically relevant genomic alterations, gene fusions, and DNA repair deficiencies. 'With PanTracer Tissue and PanTracer Tissue + HRD we're unlocking a more complete genomic view from a single sample, giving physicians clearer answers, sooner,' said Warren Stone, President and Chief Operating Officer at NeoGenomics. 'With the addition of PanTracer Tissue + HRD, we are expanding our portfolio to address the unmet need for ovarian cancer therapy selection with the objective of improving patient care.' PanTracer Tissue and PanTracer Tissue + HRD are part of NeoGenomics' broader portfolio of precision oncology solutions designed to improve patient outcomes through high-quality, guideline-aligned testing. Revealed at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the continually expanding PanTracer portfolio reflects the company's dedicated focus on advancing diagnostic tools that support more informed, personalized care. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'can,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the potential impact of PanTracer™ Tissue, including the use of HRD testing, in oncology treatment and clinical trial enrollment. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the extent of use by oncologists and biopharma companies of PanTracer™ Tissue + HRD, the speed and utility of the results generated, and the risks identified under the heading 'Risk Factors' contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and in the 'Investors' section of our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on CONTACT: Investor Contact Kendra Webster [email protected] Contact Andrea Sampson [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA INDUSTRY KEYWORD: RESEARCH MEDICAL DEVICES GENETICS CLINICAL TRIALS BIOTECHNOLOGY RADIOLOGY HEALTH SCIENCE ONCOLOGY SOURCE: NeoGenomics, Inc. Copyright Business Wire 2025. PUB: 06/30/2025 07:05 AM/DISC: 06/30/2025 07:05 AM
